In:
Cancer, Wiley, Vol. 120, No. 2 ( 2014-01-15), p. 181-189
Abstract:
The addition of brivanib to cetuximab in patients with K‐ RAS wild‐type, chemotherapy‐refractory, metastatic colorectal cancer was found to shorten time to worsening of quality of life on the Physical Function and Global scales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30. Compared with a randomized control group receiving cetuximab and placebo, patients treated with the 2‐drug combination experienced higher rates of grade 3 or greater fatigue and gastrointestinal adverse events.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink